{
    "nct_id": "NCT03335670",
    "official_title": "Biodistribution of Ga-68 Pentixafor in Patients With Neuroendocrine Tumors",
    "inclusion_criteria": "1. Age â‰¥ 18 years\n2. Histological diagnosis of neuroendocrine tumor (NET).\n3. Had a prior 68Ga DOTATATE PET/CT scan (NetSpot) and a CT or MRI with or without contrast performed within 3 months before signing the consent, without interval treatment other than a somatostatin analog.\n4. CT or MRI must demonstrate at least one lesion (primary or metastatic) present 1.5 cm or larger in any dimension on cross-sectional imaging (CT or MRI) obtained within 3 months of study enrollment.\n5. Results of CXCR4 immunohistochemistry or slides from biopsy of primary tumor or metastatic lesions available for study analysis.\n6. Participation in the Iowa Neuroendocrine Tumor Registry.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring hospitalization, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n2. Physical limitation that would limit compliance with the study requirements\n3. Pregnant or lactating women. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A negative pregnancy test will be required for all female subjects with child bearing potential.\n4. Planned administration of any NET therapy between scan 1 and 2, except for Somatostatin analog.",
    "miscellaneous_criteria": ""
}